To the content
2 . 2022

COVID-19 infection and myocarditis after surgical left ventricle reconstruction in patient with hypertrophic cardiomyopathy


It has now been shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  causing a new COVID-19 infection, can penetrate the myocardium and have both direct damaging and toxic effects. The main cardiac manifestations of this disease are fulminant myocarditis, atrial and ventricular arrhythmias, and heart failure. Cardiac arrhythmias are common complication not only in adult patients, but also in children. In this paper, we present a clinical case of the young female patient who successfully underwent operation because of a submitral (diffuse-generalized) form  of HCM, with a long event-free postoperative course, and with the rapid cardiac dysfunction, syncopes and cardiac arrhythmias after COVID-19 infection. Syncopes were caused by self-terminating short runs of ventricular tachycardia that did not trigger ICD shock. After the medical treatment  of myocarditis, she has a clinical improvement and further favorable postoperative period.

Keywords:hypertrophic cardiomyopathy (HCM); submitral HCM; MYH7; coronavirus; myocarditis; sudden cardiac death

Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Dzemeshkevich S.L., Motreva A.P., Мартьянова Yu.B., Kalmykova O.V., Dombrovskaya A.V., Nikituk T.G., Podolyak D.G., Polyak M.E., Zaklyazminskaya E.V. COVID-19 infection and myocarditis after surgical left ventricle reconstruction in patient with hypertrophic cardiomyopathy. Clinical and Experimental Surgery. Petrovsky Journal. 2022; 10 (2): 13–8.  DOI:  (in Russian)


1. Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K.,  Marelli-Berg F.M., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; 116 (10): 1666–87. DOI:  

2. Sergienko I.V., Rezinkina P.K. New coronavirus infection COVID-19 and cardiovascular diseases. Therapy features. Ateroskleroz i dislipidemii [Atherosclerosis and Dyslipidemia]. 2021; 2 (43): 5–23. (in Russian)

3. Babaev M.A., Petrushin M.A., Dubrovin I.A., et al. Acute myocardial damage with coronavirus disease 2019 (COVID-19) (case study). Clinical and Experimental Surgery. Petrovsky Journal. 2020; 8 (3): 87–94. (in Russian)

4. Blagova O.V., Sedov A.V., Savina P.O., et al. Obstructive hypertrophic cardiomyopathy in association with chronic exudative pericarditis and COVID-19. Clinical and Experimental Surgery. Petrovsky Journal. 2020; 8 (3): 95–109. (in Russian)

5. Kohli U., Meinert E., Chong G., Tesher M., Jani P. Fulminant myocarditis and atrial fibrillation in child with acute COVID-19.  J Electrocardiol. 2020; Oct 18: S0022-0736(20)30571-9. DOI:  

6. Maron B.J., Shen W.-K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillator for prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342: 365–73.

7. Ryzhkova O., Kardymon O., Prokhorchuk E., Konovalov F.,  Maslennikov A., Stepanov V., et al. Guidelinies for interpretation of the human DNA sequencing data by massive parallele sequencing methods (MPS) (ed. 2018, version 2). Meditsinskaya genetika [Medical Genetics]. 2019; 18 (2): 3–23. DOI:  (in Russian)

8. Trivedi A., Knight B.P. ICD Therapy for primary prevention in hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev. 2016; 5 (3): 188–98.

9. Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P., et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142 (25): e558–631. DOI:  

10.   Dzemeshkevich S.L., Motreva A.P., Kalmykova O.V., et al.  Hypertrophic cardiomyopathy in young: phenotype, genotype and treatment approaches. Clinical and Experimental Surgery. Petrovsky Journal. 2019; 7 (3): 54–62. (in Russian)

Sergey L. Dzemeshkevich
MD, Professor (Moscow, Russia)
Medicine today

Уважаемые коллеги! Представляем оргкомитет 17-го Национального конгресса терапевтов (с международным участием) , который состоится 12-14 октября в МВЦ "Крокус Экспо" (павильон 3, Зал 20, г. Москва). · Президент Российского научного медицинского общества терапевтов,...

IV Съезд онкологов Московской области 7 октября 2022 года Активное развитие онкологической службы позволяет эффективно решать проблемы, возникающие на всех уровнях оказания помощи пациентам с онкозаболеваниями. Одним из успешных примеров такого взаимодействия является IV...

II Всероссийская конференция с международным участием "Воспаление глаза" 12 ноября 2022 года, Москва Воспалительные заболевания глаза - широко распространенная и многогранная проблема, с которой может столкнуться в своей практике любой специалист. Найти оптимальные алгоритмы...

Journals of «GEOTAR-Media»